ARS Pharmaceuticals Inc (NASDAQ: SPRY) kicked off on Monday, up 3.45% from the previous trading day, before settling in for the closing price of $16.52. Over the past 52 weeks, SPRY has traded in a range of $8.85-$18.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -1891.25%. With a float of $55.56 million, this company’s outstanding shares have now reached $98.13 million.
In an organization with 160 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 90.74%, operating margin of -27.87%, and the pretax margin is -15.82%.
ARS Pharmaceuticals Inc (SPRY) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of ARS Pharmaceuticals Inc is 43.43%, while institutional ownership is 53.66%. The most recent insider transaction that took place on Jul 01 ’25, was worth 254,860. In this transaction Chief Commercial Officer of this company sold 15,000 shares at a rate of $16.99, taking the stock ownership to the 10,315 shares. Before that another transaction happened on Jun 27 ’25, when Company’s 10% Owner sold 740,149 for $18.46, making the entire transaction worth $13,663,151. This insider now owns 4,887,254 shares in total.
ARS Pharmaceuticals Inc (SPRY) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -1891.25% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
Take a look at ARS Pharmaceuticals Inc’s (SPRY) current performance indicators. Last quarter, stock had a quick ratio of 10.74. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.16, a number that is poised to hit -0.46 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Let’s dig in a bit further. During the last 5-days, its volume was 1.77 million. That was better than the volume of 1.56 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 31.72%.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 79.66%, which indicates a significant increase from 56.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.42% in the past 14 days, which was lower than the 69.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.81, while its 200-day Moving Average is $13.61. However, in the short run, ARS Pharmaceuticals Inc’s stock first resistance to watch stands at $17.85. Second resistance stands at $18.60. The third major resistance level sits at $19.31. If the price goes on to break the first support level at $16.39, it is likely to go to the next support level at $15.68. Assuming the price breaks the second support level, the third support level stands at $14.93.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
The company with the Market Capitalisation of 1.68 billion has total of 98,214K Shares Outstanding. Its annual sales at the moment are 89,150 K in contrast with the sum of 8,000 K annual income. Company’s last quarter sales were recorded 7,970 K and last quarter income was -33,940 K.
